Cardiac stress-responsive mechanism and its theraprutic application

心脏应激反应机制及其治疗应用

基本信息

  • 批准号:
    11307013
  • 负责人:
  • 金额:
    $ 5.76万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (A).
  • 财政年份:
    1999
  • 资助国家:
    日本
  • 起止时间:
    1999 至 2000
  • 项目状态:
    已结题

项目摘要

In response to ischemic stress, oxygen radical has been found to be a key mediator, which subsequently induces anti-oxidant effectors such as adenosine, as well as Mn-SOD.This process should explain how ischemic preconditioning is beneficial for the protection against ischemic stress. We aimed to determine how the exogenous stress induces the protective effects in the heart.(1) Mechanism of stress resistance induced in the cardiac myocytes.We used rat cardiac myocytes, endothelial cells and smooth muscle cells as cell model, and treated them with ischemia-reperfusion, heat schock and stretch stress. After treatment, we examined effector molecule such as ecto-5'-nucleatidase and Mn-SOD by measuring their protein expression and activities. Both protein and activities of these molecules were increased. When cardiac cells were overexpressed with each of these molecules, cells over-expressing molecule showed resistance against various stresses.(2) Intracellular signaling pathways in the cardiac cells in response to stresses.Oxygen radicals, proposed to be a major mechanism in stress-response, was measured by using fluorescence assay system, and found to be increased in the cytosol after various types of stresses. By the biochemical analysis of intracellular signal molecules, PK-C, MAPK, JNK, P38, and S6 kinase, we found that JNK, P38, and S6 kinase are important for the induction of stress-response signaling. Thus, the final effector such as Mn-SOD should be increased by these molecules.In conclusion, we determined the intracellular signaling pathway involved in the stress-response. P38 and S6 kinase were identified to be key mediators in this process.
在缺血应激反应中,氧自由基是一个重要的介导因子,它可以诱导腺苷和Mn-SOD等抗氧化剂的产生,这一过程可以解释缺血预处理是如何对缺血应激产生保护作用的。我们的目的是确定外源性应激如何诱导心脏的保护作用。(1)心肌细胞抗应激机制的研究以大鼠心肌细胞、血管内皮细胞和平滑肌细胞为细胞模型,分别进行缺血再灌注、热休克和牵张应激处理。治疗后,我们通过测定其蛋白表达和活性来检测效应分子如外-5 '-核肽酶和Mn-SOD。这些分子的蛋白质和活性均增加。当心肌细胞过表达这些分子中的每一种时,过表达分子的细胞显示出对各种应激的抗性。(2)心肌细胞对应激反应的细胞内信号通路利用荧光分析系统测定了被认为是应激反应的主要机制的氧自由基,发现在各种类型的应激后,细胞质中的氧自由基增加。通过对细胞内信号分子PK-C、MAPK、JNK、P38和S6激酶的生化分析,我们发现JNK、P38和S6激酶在诱导应激反应信号中起重要作用。因此,这些分子应该是增加最终效应物如Mn-SOD。总之,我们确定了参与应激反应的细胞内信号通路。P38和S6激酶被确定为该过程中的关键介质。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tetsuo Minamino: "Inhibition of Nitric Oxide Synthesis Induces Coronary Vascular Remodeling and Cardiac Hypertrophy Associated with the Activation of p70 S6 Kinase in Rats."Cardiovascular Drugs and Therapy. 14. 533-542 (2000)
Tetsuo Minamino:“抑制一氧化氮合成会诱导大鼠冠状血管重塑和心脏肥大,这与 p70 S6 激酶的激活有关。”心血管药物和治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kitakaze M et al.: "Intracoronary administration of adenosine triphosphate increases coronary blood flow and attenuates the severity of myocardial ischemic injury in dogs"Cardiovasc Drugs Ther. 13. 407-414 (1999)
Kitakaze M 等人:“冠状动脉内给予三磷酸腺苷可增加冠状动脉血流量并减轻狗心肌缺血性损伤的严重程度”Cardiovasc Drugs Ther。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Tetsuo Minamino: "Chronic Treatment with FK506 Increase p70 S6 Kinase Activity associated with Reduced Nitric Oxide Sybthase Activity in Rabbit Hearts"Cardiovascular Drugs and Therapy. 14. 329-336 (2000)
Tetsuo Minamino:“用 FK506 进行慢性治疗会增加兔心脏中与减少一氧化氮合酶活性相关的 p70 S6 激酶活性”心血管药物和治疗。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kitakaze M, Takashima S, Minamino T, Node K, Shinozaki Y, Mori H, Kuzuya T, Hori M: "Improvement by 5-Amino-4-imidazole carboxamide riboside of the contractile dysfunction that follows brief periods of ischemia through increases in ecto-5'-nucleotidase ac
Kitakaze M、Takashima S、Minamino T、Node K、Shinozaki Y、Mori H、Kuzuya T、Hori M:“5-氨基-4-咪唑甲酰胺核苷通过增加体外循环来改善短暂缺血后的收缩功能障碍
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hoshida S, Yamashita N, Kuzuya T, Hori M: "Differential effects of long-term renin-angiotensin system blockade on limitation of infarct size in cholesterol-fed rabbits."Atherosclerosis. 149. 287-294 (2000)
Hoshida S、Yamashita N、Kuzuya T、Hori M:“长期肾素-血管紧张素系统阻断对胆固醇喂养兔子梗塞面积限制的不同影响。”动脉粥样硬化。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HORI Masatsugu其他文献

HORI Masatsugu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HORI Masatsugu', 18)}}的其他基金

Molecular epidemiology of acute coronary syndrome in Japan : Large-scale, prospective, multicenter clinical investigation
日本急性冠状动脉综合征的分子流行病学:大规模、前瞻性、多中心临床研究
  • 批准号:
    11794035
  • 财政年份:
    1999
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for University and Society Collaboration
Prevention of atherosclerotic plaque rupture by the regulation of oxygen radical metabolism of vascular wall cells.
通过调节血管壁细胞氧自由基代谢预防动脉粥样硬化斑块破裂。
  • 批准号:
    10557071
  • 财政年份:
    1998
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
The pathophysiological significanse and mechanism of activation of key enzyme responsible for adenosine production in ischemic preconditioning.
缺血预处理中负责腺苷产生的关键酶的病理生理意义和激活机制。
  • 批准号:
    07457171
  • 财政年份:
    1995
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of in vitro reconstituted system for investigating intracellular signal trasduction and cellular function in myocardial cells
开发用于研究心肌细胞内信号转导和细胞功能的体外重建系统
  • 批准号:
    07557057
  • 财政年份:
    1995
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
Role of calcium overload on coronary arterial stunning caused by myocardial ischemia reperfusion
钙超载对心肌缺血再灌注引起的冠状动脉顿抑的作用
  • 批准号:
    05670613
  • 财政年份:
    1993
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Cardioprotective roles of adenosine against ischemic and reperfusion injury
腺苷对缺血和再灌注损伤的心脏保护作用
  • 批准号:
    03670449
  • 财政年份:
    1991
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Role of Adrenergic Activity, Alpha-Receptor, and Beta-Receptor in Progression of Chronic Heart Failure
肾上腺素能活性、α 受体和 β 受体在慢性心力衰竭进展中的作用
  • 批准号:
    01570484
  • 财政年份:
    1989
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
Role of Neurohumoral Abnormalities and -Adrenergic Reeptor Changes in Progression of Chronic Heart Failure
神经体液异常和肾上腺素受体变化在慢性心力衰竭进展中的作用
  • 批准号:
    62570392
  • 财政年份:
    1987
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Alterations in macrophage metabolism in heart failure with preserved ejection
射血保留性心力衰竭患者巨噬细胞代谢的改变
  • 批准号:
    502586
  • 财政年份:
    2024
  • 资助金额:
    $ 5.76万
  • 项目类别:
SBIR Phase II: In-vivo validation of a volume-manufacturable and factory-calibrated wearable NT-proBNP monitoring system for heart failure treatment
SBIR II 期:用于心力衰竭治疗的可批量生产和工厂校准的可穿戴 NT-proBNP 监测系统的体内验证
  • 批准号:
    2335105
  • 财政年份:
    2024
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Cooperative Agreement
RAPHAEL - Integrating a Palliative Care Approach for Patients with Heart Failure
RAPHAEL - 为心力衰竭患者整合姑息治疗方法
  • 批准号:
    10112701
  • 财政年份:
    2024
  • 资助金额:
    $ 5.76万
  • 项目类别:
    EU-Funded
Exploratory research to elucidate the molecular mechanisms by which depression makes heart failure more severe and to reconstruct heart failure treatment strategies.
探索性研究旨在阐明抑郁症使心力衰竭更加严重的分子机制,并重建心力衰竭治疗策略。
  • 批准号:
    23K07507
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Aging of cardiac fibroblasts and heart failure: novel heart failure treatment through regeneration and transplantation of cardiac fibroblasts
心脏成纤维细胞的衰老和心力衰竭:通过心脏成纤维细胞的再生和移植治疗心力衰竭
  • 批准号:
    23K07526
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidating the Intricate Interplay between Mitochondria, Innate Immunity, and Viral Pathogenesis in Heart Failure
阐明心力衰竭中线粒体、先天免疫和病毒发病机制之间复杂的相互作用
  • 批准号:
    491149
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Fellowship Programs
Comparison of Machine Learning and Conventional Statistical Modeling for Predicting Readmission Following Acute Heart Failure Hospitalization
机器学习与传统统计模型预测急性心力衰竭住院后再入院的比较
  • 批准号:
    495410
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
Elucidation of the precise mechanism of heart failure prevention by beta-catenin inhibition enabling the future development of a novel class of medicine
阐明β-连环蛋白抑制预防心力衰竭的精确机制,有助于未来开发一类新型药物
  • 批准号:
    23K15167
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel ventricular arrhythmias mechanism in ischemic heart failure focusing on neuropeptide Y
以神经肽Y为重点的缺血性心力衰竭室性心律失常新机制
  • 批准号:
    23K15119
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of novel pathophysiology and development of treatment for heart failure using human iPS cell-derived 3D heart tissue
利用人 iPS 细胞衍生的 3D 心脏组织阐明新的病理生理学并开发心力衰竭治疗方法
  • 批准号:
    23K15140
  • 财政年份:
    2023
  • 资助金额:
    $ 5.76万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了